Risk of macrovascular complications in statin-treated patients developing diabetes. (November 2019)

• Record Type: Journal Article
• Authors: Chen, Yin-Huei; Yang, Yu-Cih; Chen, Weishan; Lin, Yen-Nien; Hung, Yi-Chih
• Is Part Of: Diabetes research and clinical practice. Volume 157(2019)
• Publication Date: 2019-11
• Subjects: Statin -- Hyperlipidemia -- Diabetes mellitus -- Macrovascular complications -- Cohort study; CV cardiovascular -- NHI Taiwan national health insurance -- NHIRD the Taiwan national health insurance research database -- LHID the longitudinal health insurance database -- ACS acute coronary syndrome -- MI myocardial infarction -- PDC proportion of follow-up days on statin use -- HTN hypertension -- CHF congestive heart failure -- CKD chronic renal disease -- WOSCOPS the West of Scotland coronary prevention study -- JUPITER justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin; Diabetes -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462
• DOI: 10.1016/j.diabres.2019.107870
• Languages: English
• ISSNs: 0168-8227

Abstract

Abstract: Aims: To assess the risk of macrovascular complications in patients developing diabetes from statin treatment. Methods: In this population-based cohort study, 40, 409 participants who began to receive statin therapy between 2000 and 2012 were enrolled in to the study group, and another 1:1 matched adults without statin treatment during the same period served as the control group. Both groups were followed up to identify individuals who later developed diabetes. After a follow-up identification of diabetes, diabetes and non-diabetes cohorts were subjected to an analysis for the risk of macrovascular events between diagnosis of diabetes and December 31, 2013. Results: Compared with individuals without statin therapy, statin-treated patients had a higher risk of developing diabetes (adjusted hazard ratio: 2.46; 95% confidence interval: 2.37–2.57). Compared with statin-treated patients without diabetes, statin-treated participants developing diabetes had a higher overall incidence of macrovascular complications (adjusted hazard ratio: 1.74; 95% confidence interval: 1.62–1.88). Moreover, compared with that of other diabetogenic statins, patients taking pravastatin had a lower risk of developing diabetes (adjusted hazard ratio: 0.63; 95% confidence interval: 0.55–0.73) and macrovascular events (adjusted hazard ratio: 0.64; 95% confidence interval: 0.42–0.98). Conclusions: According to these findings, prescribing statins that have a neutral effect on glucose homeostasis may be advisable for Asian populations.